Drug Development Pipeline
Restore CFTR Function
GLPG2222 is a new CFTR corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.
A phase 2a study to test the safety and tolerability of GLPG2222 in people with CF who have two copies of the F508del CFTR mutation is underway.
This program is sponsored by Galapagos and is being conducted within the Therapeutics Development Network.
Recent GLPG2222 Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More